Castle Study Shows Boosted Reyataz(R) (Atazanavir) Is A Well Tolerated And Effective Option For Treatment-Naïve Patients

The week-48 results of the CASTLE study were announced at the 15th Conference on Retroviruses and Opportunistic Infections (CROI) and showed boosted atazanavir to be as efficacious in antiretroviral-naive HIV-1 patients as lopinavir/ritonavir.

More: continued here

Filed under: Clinical Trials on February 13th, 2008